|
시장보고서
상품코드
2050643
유전성 강직성 하반신마비 시장 : 유형별, 치료법별, 투여 경로별, 유통 채널별, 환자별, 지역별Hereditary Spastic Paraplegia Market, By Type, By Therapeutics,By Route of Administration, By Distribution Channel, By Patient, By Geography |
||||||
유전성 강직성 하반신마비 시장은 2026년에 1억 9,480만 달러로 추정되고 있으며, 2033년에 3억 2,110만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.4%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 1억 9,480만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.40% | 2033년 시장 규모 예측 : | 3억 2,110만 달러 |
유전성 경련성 대마비(HSP)는 대뇌피질 척수로의 축삭 변성으로 인해 하반신의 진행성 근력저하와 경련을 특징으로 하는 다양한 유전성 신경질환군입니다. 전 세계 유전성 경련성 하반신 마비 시장은 전 세계 인구 10만 명당 약 3-10명이 앓고 있는 이 복잡한 질병을 관리하기 위해 고안된 의약품, 의료기기, 진단 툴, 치료 서비스 등을 포함하고 있습니다. 80가지 이상의 유전적 아형이 확인되었으며, 이들은 순수형 또는 복합형으로 분류됩니다. HSP는 임상적으로 큰 이질성을 보이고 있으며, 이는 개인별 맞춤 치료 접근에 대한 수요를 견인하고 있습니다. 유전자 검사 기술의 발전, 질병의 병태생리에 대한 이해의 심화, 유전자 치료와 새로운 약물 요법을 포함한 새로운 치료법의 등장으로 시장 상황은 빠르게 변화하고 있습니다. 현재 치료 패러다임은 주로 항경련제, 물리치료, 보조기구를 통한 증상 관리에 중점을 두고 있지만, 연구 파이프라인에서는 질병 변형 요법이 점점 더 강조되고 있습니다.
시장 역학
전 세계 유전성 경련성 하반신 마비(HSP) 시장의 성장은 주로 질병에 대한 인식의 증가와 진단 능력의 향상, 특히 HSP의 하위 유형을 보다 빠르고 정확하게 식별할 수 있는 첨단 유전자 검사 기술에 의해 주도되고 있습니다. 선진국의 의료비 증가와 더불어 희귀질환 연구개발에 대한 투자 확대, 제약사 및 생명공학 기업이 표적치료제 개발에 막대한 자원을 투입하고 있으며, 시장 확대에 큰 힘을 실어주고 있습니다. 또한 연구개발의 활성화와 규제 당국의 승인이 결합되어 분석 기간 중 시장이 확대될 것으로 예상됩니다. 2026년 4월 28일, 희귀 신경질환 치료제 개발에 주력하는 임상 단계의 유전자 치료제 기업 BlackfinBio Ltd는 미국 식품의약국(FDA)이 유전성 경련성 대마비 47형(HSP47) 소아를 대상으로 한 자사의 신규 아데노연관바이러스(AAV) 유전자치료제 BFB-101의 1/2상 임상시험계획(IND) 승인 발표(SPG47) 소아 대상 1/2상 임상시험에 대해 미국 식품의약국(FDA)이 임상시험계획(IND)을 승인했다고 발표했습니다. SPG47은 소아에서 진행성 하지 경련, 발달 지연, 지적 장애를 특징으로 하는 희귀 상염색체 열성 유전성 신경질환입니다.
본 연구의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 매출 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 전 세계 유전성 경련성 마비 시장의 주요 참가업체를 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계의 유전성 경련성 마비 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 유전성 경련성 마비 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 유전성 강직성 하반신마비 시장 : 유형별, 2021-2033년
제5장 세계의 유전성 강직성 하반신마비 시장 : 치료법별, 2021-2033년
제6장 세계의 유전성 강직성 하반신마비 시장 : 투여 경로별, 2021-2033년
제7장 세계의 유전성 강직성 하반신마비 시장 : 유통 채널별, 2021-2033년
제8장 세계의 유전성 강직성 하반신마비 시장 : 환자별, 2021-2033년
제9장 세계의 유전성 강직성 하반신마비 시장 : 유통 채널별, 2021-2033년
제10장 세계의 유전성 강직성 하반신마비 시장 : 지역별, 2021-2033년
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌과 조사 방법
KSA 26.06.10Hereditary Spastic Paraplegia Market is estimated to be valued at USD 194.8 Mn in 2026 and is expected to reach USD 321.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 194.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.40% | 2033 Value Projection: | USD 321.1 Mn |
Hereditary spastic paraplegia (HSP) represents a diverse group of inherited neurological disorders characterized by progressive weakness and spasticity of the lower limbs, stemming from degeneration of corticospinal tract axons. The global hereditary spastic paraplegia market encompasses pharmaceutical interventions, medical devices, diagnostic tools, and therapeutic services designed to manage this complex condition affecting approximately 3-10 individuals per 100,000 worldwide. With over 80 identified genetic subtypes classified as either pure or complicated forms, HSP presents significant clinical heterogeneity that drives demand for personalized treatment approaches. The market landscape is evolving rapidly due to advancing genetic testing capabilities, improved understanding of disease pathophysiology, and emerging therapeutic modalities including gene therapy and novel pharmacological interventions. Current treatment paradigms primarily focus on symptom management through antispastic medications, physical therapy, and assistive devices, while research pipelines increasingly emphasize disease-modifying therapies.
Market Dynamics
The global hereditary spastic paraplegia market growth is primarily driven by increasing disease awareness and improved diagnostic capabilities, particularly through advanced genetic testing technologies that enable earlier and more accurate identification of HSP subtypes. Rising healthcare expenditure in developed nations, coupled with growing investment in rare disease research and development, significantly propels market expansion as pharmaceutical companies and biotechnology firms allocate substantial resources toward developing targeted therapies. Moreover, increasing research and development coupled with regulatory approval is expected to augment the market over the analysis period. For instance, on April 28, 2026, BlackfinBio Ltd, a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases, announced that the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for a Phase 1/2 clinical trial of its novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47). SPG47 is a rare, autosomal-recessive, neurological disorder characterized by progressive lower-limb spasticity, developmental delays and intellectual disability in children.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hereditary spastic paraplegia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Piramal Pharma Limited (PPL), Camber Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Nexus Pharmaceuticals, LLC, AdvaCare Pharma, Pfizer Inc., Genentech, Inc. (F. Hoffmann-La Roche AG), AbbVie Inc., Merz Pharmaceuticals, LLC., Ipsen Biopharmaceuticals, Inc., and Other Prominent Players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global hereditary spastic paraplegia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary spastic paraplegia market.
Market Segmentation
- Type Insights (Revenue, USD Mn, 2021 - 2033)
- Pure
- Complicated
- Therapeutics Insights (Revenue, USD Mn, 2021 - 2033)
- Muscle Relaxants
- Baclofen
- Tizanidine
- Dantrolene
- Pain Management
- Gabapentin or Pregabalin
- Benzodiazepines
- Diazepam
- Clonazepam
- Botulinum Toxin Injections
- Others (Anticholinergic medications, etc.)
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Patient Demographics Insights (Revenue, USD Mn, 2021 - 2033)
- Adults
- Pediatrics
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Online Pharmacies
- Retail Pharmacies
- Hospitals Pharmacy
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Teva Pharmaceuticals USA, Inc.
- Amneal Pharmaceuticals LLC
- Piramal Pharma Limited (PPL)
- Camber Pharmaceuticals, Inc.
- ANI Pharmaceuticals, Inc.
- Nexus Pharmaceuticals, LLC
- AdvaCare Pharma
- Pfizer Inc.
- Genentech, Inc. (F. Hoffmann-La Roche AG)
- AbbVie Inc.
- Merz Pharmaceuticals, LLC.
- Ipsen Biopharmaceuticals, Inc.
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Hereditary Spastic Paraplegia Market, By Type
- Global Hereditary Spastic Paraplegia Market, By Therapeutics
- Global Hereditary Spastic Paraplegia Market, By Route of Administration
- Global Hereditary Spastic Paraplegia Market, By Distribution Channel
- Global Hereditary Spastic Paraplegia Market, By Patient Demographics
- Global Hereditary Spastic Paraplegia Market, By Distribution Channel
- Global Hereditary Spastic Paraplegia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Industry Trends
- Epidemiology
- Treatment Option Analysis
- Reimbursement Scenario
- Disease Awareness Programs
- Pipeline Analysis
- Technology Landscape
4. Global Hereditary Spastic Paraplegia Market, By Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Complicated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Hereditary Spastic Paraplegia Market, By Therapeutics, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Baclofen
- Tizanidine
- Dantrolene
- Baclofen
- Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Gabapentin or Pregabalin
- Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Diazepam
- Clonazepam
- Botulinum Toxin Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (Anticholinergic medications, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Hereditary Spastic Paraplegia Market, By Route of Administration, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Hereditary Spastic Paraplegia Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Hereditary Spastic Paraplegia Market, By Patient Demographics, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
9. Global Hereditary Spastic Paraplegia Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Hospitals Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
10. Global Hereditary Spastic Paraplegia Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Therapeutics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Demographics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Therapeutics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Demographics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Therapeutics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Demographics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Therapeutics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Demographics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Therapeutics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Demographics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Therapeutics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Demographics, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2022 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Teva Pharmaceuticals USA, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Piramal Pharma Limited (PPL)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Camber Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ANI Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nexus Pharmaceuticals, LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AdvaCare Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech, Inc. (F. Hoffmann-La Roche AG)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merz Pharmaceuticals, LLC.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Biopharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
